tradmap

IVVD Invivyd, Inc.

$0.83 +2.74%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Invivyd, Inc. (IVVD) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $244 million. Shares last traded at $0.83, 73.3% below their 52-week high. Over the past year the stock is down 20.0%. Net profit margin is -183.9%, below the peer median of 5.3%. Revenue grew 110.5% year over year.

Market Cap
$244M
Shares Out
294.8M
EPS (TTM)
$-0.96
P/E Ratio
P/S Ratio
4.18
P/B Ratio
1.35
Dividend / Share
Dividend Yield
52-Week High
$3.10
52-Week Low
$0.53
Volume
37,707
Avg Vol (3m)
144,109.032

Performance

1W
-7.95%
1M
+37.17%
3M
-24.68%
6M
-52.52%
YTD
-66.99%
1Y
-19.95%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.00
SMA (50)
$0.78
SMA (200)
$1.50
Price vs SMA50
+6.88%
Price vs SMA200
-44.90%
ATR (14)
$0.08

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$58M
Net Income
$-107M
Gross Margin
Operating Margin
-192.8%
Net Margin
-183.9%
Return on Equity
-59.3%
Return on Assets
-49.0%
Current Ratio
5.87
Debt / Equity
0.21
Revenue Growth (YoY)
+110.5%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.27 2026-08-13
Q1 2026 $-0.13 2026-05-14
FY 2025 $-0.30 2026-03-05
Q3 2025 $-0.30 2025-11-06
Q2 2026 $-0.26 2026-08-13
Q1 2026 $-0.14 2026-05-14

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

IVVD vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
4.18 / 19.49 med
-79% discount
Net margin vs peers
-183.9% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.